AR013157A1 - Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion - Google Patents

Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion

Info

Publication number
AR013157A1
AR013157A1 ARP980103182A ARP980103182A AR013157A1 AR 013157 A1 AR013157 A1 AR 013157A1 AR P980103182 A ARP980103182 A AR P980103182A AR P980103182 A ARP980103182 A AR P980103182A AR 013157 A1 AR013157 A1 AR 013157A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
independently represent
nucleotide analog
composition including
Prior art date
Application number
ARP980103182A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013157(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR013157A1 publication Critical patent/AR013157A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Una composicion farmacéutica que comprende un análogo nucleotido y uno o más aditivos que forman cristales. Más específicamente, una composicionfarmacéutica, de acuerdo con la reivindicacion 1, donde el nucleotido es un compuesto de la formula(I), donde R1 y R2 representan en formaindependiente hidrogeno o halogeno; R3 y R4 representan en forma independiente fenilo, o alquilo C1-6, opcionalmente sustituido por uno o mássustituyentes seleccionados de OR5, alquiltio C1-6, NR6R7, fenilo, COOR8 y alogeno, R5, R6, R7 y R8 independientemente representan hidrogeno o alquiloC1-6 y X representa una porcion acídica, o una sal farmacéuticamente aceptable de los mismos; y proceso para la preparacion de esta composicionfarmacéutica que incluye el mezclado de los ingredientes de la composicion, y ya sea el congelado y secado de la mezcla congelada o el secado de la mismamediante pulverizado. La composicion es util en terapia particularmente en el tratamiento de angina.
ARP980103182A 1997-07-11 1998-06-30 Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion AR013157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
AR013157A1 true AR013157A1 (es) 2000-12-13

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103182A AR013157A1 (es) 1997-07-11 1998-06-30 Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion

Country Status (36)

Country Link
US (1) US6130208A (es)
EP (1) EP1000079B1 (es)
JP (1) JP4950380B2 (es)
KR (1) KR100786654B1 (es)
CN (2) CN1864696A (es)
AR (1) AR013157A1 (es)
AT (1) ATE340801T1 (es)
AU (1) AU8362598A (es)
BR (1) BR9810703A (es)
CA (1) CA2295628C (es)
CY (1) CY1105805T1 (es)
CZ (1) CZ298110B6 (es)
DE (1) DE69836023T2 (es)
DK (1) DK1000079T3 (es)
EE (1) EE04119B1 (es)
ES (1) ES2273425T3 (es)
HK (1) HK1026429A1 (es)
HU (1) HU226489B1 (es)
ID (1) ID24716A (es)
IL (2) IL133868A0 (es)
IS (1) IS2439B (es)
MY (1) MY116421A (es)
NO (1) NO329918B1 (es)
NZ (1) NZ502073A (es)
PL (1) PL192768B1 (es)
PT (1) PT1000079E (es)
RU (1) RU2216330C2 (es)
SA (1) SA98190328B1 (es)
SE (1) SE9702680D0 (es)
SI (1) SI1000079T1 (es)
SK (1) SK285766B6 (es)
TR (1) TR200000006T2 (es)
TW (1) TW585764B (es)
UA (1) UA65576C2 (es)
WO (1) WO1999002542A1 (es)
ZA (1) ZA985669B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986281B2 (ja) * 2004-10-05 2012-07-25 旭化成ファーマ株式会社 補酵素の安定化方法およびその組成物
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
ES2470329T3 (es) 2009-08-28 2014-06-23 Daiichi Sankyo Company, Limited Derivado del ácido 3-(biariloxi) priopi�nico
AU2010319612B2 (en) 2009-11-11 2016-01-14 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2819548C (en) * 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
ES2657019T3 (es) 2011-08-17 2018-03-01 Samuel Shiber Catéter giratorio adaptativo para abrir vasos corporales obstruidos
BR112015022070B1 (pt) 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MA41326A (fr) 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (es) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
AU3095092A (en) * 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
JP3083156B2 (ja) * 1993-02-10 2000-09-04 アストラ・フアーマシユウテイカルズ・リミテツド Ｎ−アルキル−２−置換ａｔｐ類似体
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
CN1263533A (zh) 2000-08-16
SK183699A3 (en) 2000-07-11
ES2273425T3 (es) 2007-05-01
TW585764B (en) 2004-05-01
BR9810703A (pt) 2000-08-08
HK1026429A1 (en) 2000-12-15
PL192768B1 (pl) 2006-12-29
CA2295628C (en) 2008-07-29
HUP0002622A3 (en) 2002-04-29
AU8362598A (en) 1999-02-08
IS2439B (is) 2008-11-15
ID24716A (id) 2000-08-03
ZA985669B (en) 1999-01-11
TR200000006T2 (tr) 2000-07-21
IS5331A (is) 1999-12-30
KR100786654B1 (ko) 2007-12-21
DE69836023D1 (de) 2006-11-09
CY1105805T1 (el) 2011-02-02
PT1000079E (pt) 2006-12-29
MY116421A (en) 2004-01-31
SA98190328B1 (ar) 2006-08-15
CN1864696A (zh) 2006-11-22
JP2001509512A (ja) 2001-07-24
IL133868A0 (en) 2001-04-30
NZ502073A (en) 2001-09-28
EP1000079B1 (en) 2006-09-27
EP1000079A1 (en) 2000-05-17
IL133868A (en) 2010-05-17
KR20010021647A (ko) 2001-03-15
CZ200083A3 (cs) 2000-06-14
CZ298110B6 (cs) 2007-06-27
RU2216330C2 (ru) 2003-11-20
NO329918B1 (no) 2011-01-24
WO1999002542A1 (en) 1999-01-21
ATE340801T1 (de) 2006-10-15
PL337970A1 (en) 2000-09-11
EE04119B1 (et) 2003-08-15
CA2295628A1 (en) 1999-01-21
EE200000022A (et) 2000-10-16
SI1000079T1 (sl) 2007-08-31
JP4950380B2 (ja) 2012-06-13
DK1000079T3 (da) 2006-11-20
US6130208A (en) 2000-10-10
UA65576C2 (uk) 2004-04-15
NO20000123D0 (no) 2000-01-10
HUP0002622A2 (hu) 2001-05-28
HU226489B1 (en) 2009-03-02
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
NO20000123L (no) 2000-03-03
SE9702680D0 (sv) 1997-07-11

Similar Documents

Publication Publication Date Title
AR013157A1 (es) Composicion farmaceutica que incluye un analogo nucleotido y proceso para su preparacion
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
NO984120L (no) Triarylforbindelser
PE107699A1 (es) Derivados de oxindol sustituidos
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
NO870384L (no) Nye fenoliske tioetere som inhibitorer for 5-lipoksygenase
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO965012D0 (no) Farmasöytisk preparat som omfatter glukagon
HUT77344A (hu) Orto-szubsztituált-benzol- és -piridin-származékok, és az ezeket tartalmazó gyógyszerkészítmények
HUP9901074A2 (hu) Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
AR010377A1 (es) Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.
ATE99931T1 (de) Inhibitoren fuer zellenzuwachs und methoden fuer krebsbehandlung.
HUP0004644A2 (hu) Neutrofil elasztáz inhibitor hatású pirrolo-pirrolon-származékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
HUP0002106A2 (hu) Transz-5-klór-2,3,3a,12b-tetrahidro-2-metil-1H-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol aromás szulfonátjai és az ezt tartalmazó gyógyszerkészítmények
HUP0201910A2 (hu) Új aminobenzofenonszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE253359T1 (de) Antithrombotische mittel
AR033828A1 (es) Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica
AR009484A1 (es) Un compuesto de acido n-sustituido-2-amino-4-fenil-4-oxo-butanoico, su utilizacion como inhibidor de la quinurenina-3-hidroxilasa y una composicionfarmaceutica que lo comprende.
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
ATE286395T1 (de) Antithrombotische mittel

Legal Events

Date Code Title Description
FC Refusal